title: Hepatitis B virus infection in hemodialysis populations: progress toward prevention.
abstract: Hemodialysis patients are at increased risk of acquiring hepatitis B virus (HBV) infection. Administration of the standard HBV vaccine is suboptimal as a means of prevention because of an impaired seroconversion response in individuals with chronic kidney disease. Surquin and colleagues describe a novel vaccine adjuvant system that increases speed of seroconversion and duration of seroprotection compared with older vaccine formulations. However, its ability to improve overall seroconversion response remains unproven.
authors.affiliation: Department of Nephrology, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia. katherine_barraclough@health.qld.gov.au
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Barraclough
authors.forename: E Geoffrey
authors.initials: EG
authors.lastname: Playford
mesh_terms: D006509:Hepatitis B / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D006435:Renal Dialysis / Q000009:adverse effects
chemical_list: D017325:Hepatitis B Vaccines